Unlike current methods that predominantly focus on loss of function, LoGoFunc distinguishes among different types of harmful mutations, offering potentially valuable insights into diverse disease outcomes. The findings were described in the November 30 online issue of Genome Medicine https://doi.org/10.1186/s13073-023-01261-9.
Genetic variations can alter protein function, with some mutations boosting activity or introducing new functions (gain of function), while others diminish or eliminate function (loss of function). These changes can have significant implications for human health and treatment of disease.
“Tools presently available fall short in differentiating between gain and loss of function, which motivated us to develop LoGoFunc. This matters because these variants impact protein activity differently, influencing disease outcomes. We created an innovative tool that addresses a critical gap in the field, providing a practical way to understand the functional consequences of genetic variations on a larger scale,” says co-senior corresponding author Yuval Itan, PhD, Associate Professor of Genetics and Genomic Sciences and a core member of The Charles Bronfman Institute for Personalized Medicine at Icahn Mount Sinai.
LoGoFunc uses machine learning trained on a database of known pathogenic gain-of-function and loss-of-function mutations identified in the literature. It considers a wide range of 474 biological features, including data from protein structures predicted by AlphaFold2 and network features reflecting human protein interactions. Tested on sets from the Human Gene Mutation Database and ClinVar, LoGoFunc demonstrated high accuracy in predicting gain-of-function, loss-of-function, and neutral variants, according to the investigators.
“Beyond personalized medicine, LoGoFunc has implications for drug discovery, genetic counseling, and accelerating genetic research. Its accessibility promotes collaboration and offers a comprehensive view of variant impact across the human genome,” says co-senior corresponding author Avner Schlessinger, PhD, Professor of Pharmacological Sciences and Associate Director of the Mount Sinai Center for Therapeutics Discovery. “Therefore, we believe that LoGoFunc holds promise for precision medicine, enabling the possibility of more tailored treatments based on an individual's genetic makeup.”
The investigators caution that while these findings are a significant step forward, translating them into clinical applications requires further validation and integration with other medical information. LoGoFunc's predictions are based on training data and inherent assumptions. Ongoing validation efforts are crucial for reliable outcomes. As genetic data continues to grow, refining LoGoFunc's capabilities and extending its scope are priorities for future research.
“By bridging the gaps, the tool enhances our understanding of genetic variations that contribute to diseases, paving the way for personalized treatment strategies and drug discovery,” says study first author David Stein, a PhD candidate at Icahn Mount Sinai. “We believe that LoGoFunc will be a powerful tool for deciphering the functional consequences of genetic variations. While its potential applications are vast, ongoing validation efforts will ensure its real-world impact.”
The tool's predictions for missense variants across the entire genome are accessible for non-commercial use and analysis at https://itanlab.shinyapps.io/goflof/.
The paper is titled “Genome-wide prediction of pathogenic gain- and loss-of-function variants from ensemble learning of a diverse feature set.”
The remaining authors, all with Icahn Mount Sinai except where indicated, are Meltem Ece Kars, PhD; Yiming Wu, PhD (Icahn Mount Sinai and China West Normal University); Çiğdem Sevim Bayrak, PhD; Peter D. Stenson, B.Sc. (Cardiff University); and David N. Cooper, PhD (Cardiff University).
The study was funded by the Leducq Foundation, Helmsley Foundation (2209–05535), the Charles Bronfman Institute for Personalized Medicine, and the National Institutes of Health (U01 CA271318, R01 GM108911 and R01 CA277794).
-####-
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight- member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.
Ranked 14th nationwide in National Institutes of Health (NIH) funding and among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators, and clinicians work within and across 44 academic departments and 36 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, as well as gastrointestinal and liver diseases.
Icahn Mount Sinai offers highly competitive MD, PhD, and Master’s degree programs, with current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,000 clinical residents and fellows training throughout the Health System. In addition, more than 550 postdoctoral research fellows are in training within the Health System.
A culture of innovation and discovery permeates every Icahn Mount Sinai program. Mount Sinai’s technology transfer office, one of the largest in the country, partners with faculty and trainees to pursue optimal commercialization of intellectual property to ensure that Mount Sinai discoveries and innovations translate into healthcare products and services that benefit the public.
Icahn Mount Sinai’s commitment to breakthrough science and clinical care is enhanced by academic affiliations that supplement and complement the School’s programs.
Through the Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai. Additionally, MSIP develops research partnerships with industry leaders such as Merck & Co., AstraZeneca, Novo Nordisk, and others.
The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem, and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinai’s location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally.
-------------------------------------------------------
* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Beth Israel; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.
END
